After evaluating gender (female vs male), age status (<18 vs ≥18 months), MYCN amplification (non-amplified vs amplified), Children’s Oncology Group (COG) risk status (low risk vs high risk), and International Neuroblastoma Staging System (INSS) stage (INSS 1 vs INSS 4), it was determined that the FRG signature plays an independent prognostic role (Training cohort: HR = 2.438, 95% CI = 1.753–3.390, p < 0.001; validation cohort: HR = 16.652, 95% CI = 5.227–53.052, p < 0.001; Figures 4B,D). Here, MYCN is linked to neuroblastoma.